title: The role of GM-CSF in the treatment of acute myeloid leukemia.
abstract: After a first study showed that GM-CSF following chemotherapy effectively accelerated neutrophil recovery and reduced early mortality in high risk patients with AML, a second study was begun in which GM-CSF was applied preceding chemotherapy and continuing until neutrophil recovery in the initial 5 chemotherapy courses for patients with newly diagnosed AML. The CR rate in patients of 16-75 (median 50) years was 75% in GM-CSF patients and 84% in controls. GM-CSF patients showed a trend to more frequent rapid blast clearance and fewer persistent leukemias and a significantly superior remission duration as of this update two-and-a-half years after the study started. It should be shown later by this study whether GM-CSF multiple course priming and longterm administration adds to the cure rate of patients with AML.
authors.affiliation: Department of Internal Medicine, University of Münster, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Büchner
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: B
authors.initials: B
authors.lastname: Wörmann
authors.forename: R
authors.initials: R
authors.lastname: Rottmann
authors.forename: G
authors.initials: G
authors.lastname: Maschmeyer
authors.forename: W D
authors.initials: WD
authors.lastname: Ludwig
authors.forename: M
authors.initials: M
authors.lastname: Zühlsdorf
authors.forename: K
authors.initials: K
authors.lastname: Buntkirchen
authors.forename: A
authors.initials: A
authors.lastname: Sander
authors.forename: J
authors.initials: J
authors.lastname: Aswald
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008875:Middle Aged
chemical_list: D016178:Granulocyte-Macrophage Colony-Stimulating Factor